false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
2021 Annual Global Meeting: Virtual
Plenary IV: Oral Abstract Presentations
Plenary IV: Oral Abstract Presentations
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In the first video, the IGCS 2021 Annual Global Meeting holds an award ceremony to honor 12 individuals in the global gynecologic cancer community. The award recipients give acceptance speeches expressing their gratitude and discussing their contributions to the field of gynecologic oncology. They touch on important topics such as mentorship, patient impact, access to care, and education and advocacy. The speeches showcase the recipients' dedication and commitment to advancing gynecologic cancer care and research. <br /><br />In the second video, three different trials in cancer treatment are discussed. The first trial, ARIEL4, investigates the combination of Rucaparib and chemotherapy in patients with relapsed ovarian cancer and a BRCA mutation. The trial showed that adding Rucaparib did not significantly improve overall survival or progression-free survival compared to standard chemotherapy alone. It also identified a subgroup of patients with a BRCA reversion mutation who did not benefit as much from Rucaparib.<br /><br />The second trial, Outback, examines the use of adjuvant chemotherapy alongside standard chemoradiotherapy in patients with local regionally advanced cervical cancer. The trial found that adding adjuvant chemotherapy did not enhance overall survival or progression-free survival compared to chemoradiotherapy alone.<br /><br />The third trial, Keynote 775, evaluates the combination of Lenvatinib and Pembrolizumab in patients with advanced endometrial cancer. Results showed that the combination significantly improved overall survival, progression-free survival, and objective response rate compared to standard treatment. However, it also exhibited a higher rate of treatment-related adverse events and dose interruptions.<br /><br />Overall, these trials provide valuable insights into the effectiveness and safety of various treatment approaches for ovarian, cervical, and endometrial cancer.
Keywords
IGCS 2021 Annual Global Meeting
award ceremony
gynecologic cancer community
acceptance speeches
ARIEL4 trial
Rucaparib
chemotherapy
relapsed ovarian cancer
BRCA mutation
Outback trial
adjuvant chemotherapy
chemoradiotherapy
Keynote 775 trial
Contact
education@igcs.org
for assistance.
×